Ananda Developments Plc (AQSE:ANA) co-founder and CEO Melissa Sturgess visits the Proactive London studio to speak with Thomas Warner about the work the cannabinoid medicine development company is doing to help develop treatments for patients suffering from complex, chronic inflammatory pain conditions.
Sturgess says that cannabinoid-based medicine will ultimately become "completely ubiquitous" and highlights the various fronts that Ananda is currently pushing forward on, including two upcoming phase II randomised controlled clinical trials.